Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
Revenue of Ipca Laboratories Limited (IPCALAB.NS)
Revenue in 2023 (TTM): $916.95 M
According to Ipca Laboratories Limited's latest financial reports the company's current revenue (TTM) is $916.95 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ipca Laboratories Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $916.95 M | $364.59 M | $142.28 M | $100.28 M | $65.14 M |
| 2022 | $743.11 M | $468.62 M | $125.24 M | $88.69 M | $56.09 M |
| 2021 | $686.25 M | $435.62 M | $163.24 M | $135.16 M | $105.21 M |
| 2020 | $635.61 M | $421.19 M | $191.43 M | $164.38 M | $135.67 M |
| 2019 | $542.51 M | $339.15 M | $116.73 M | $87.93 M | $72.16 M |
| 2018 | $439.39 M | $285.83 M | $88.26 M | $65.03 M | $52.94 M |
| 2017 | $381.6 M | $241.63 M | $58.04 M | $34.57 M | $28.49 M |
| 2016 | $374.79 M | $236.26 M | $55.29 M | $32.17 M | $24.13 M |
| 2015 | $338.61 M | $206.55 M | $37.14 M | $13.72 M | $11.51 M |
| 2014 | $370.9 M | $226.91 M | $67.38 M | $42.97 M | $30.84 M |
| 2013 | $386.41 M | $245.4 M | $89.72 M | $75.04 M | $56.91 M |
| 2012 | $330.1 M | $193.71 M | $67.7 M | $54.06 M | $38.6 M |
| 2011 | $280.7 M | $172.04 M | $62.79 M | $43.36 M | $32.97 M |
| 2010 | $224.03 M | $131.64 M | $50.92 M | $40.54 M | $31.28 M |
| 2009 | $185.6 M | $108.77 M | $41.09 M | $31.69 M | $24.44 M |
| 2008 | $152.78 M | $92.41 M | $22.59 M | $14.08 M | $12 M |
| 2007 | $125.08 M | $69.88 M | $27.15 M | $20.86 M | $16.18 M |
| 2006 | $111.76 M | $64.01 M | $24.36 M | $18.36 M | $15.02 M |
| 2005 | $89.93 M | $25.21 M | $13.37 M | $8.87 M | $7.32 M |
| 2004 | $80.81 M | $24.36 M | $14.45 M | $11.2 M | $8.82 M |